Clinical Trial Update: Metronomic Capecitabine, Oxaliplatin and UGT1A1 Genotype-directed Irinotecan in Metastatic Pancreatic Cancer Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating a metronomic capecitabine/oxaliplatin regimen with UGT1A1 genotype-directed irinotecan in metastatic pancreatic cancer patients; t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Camptosar (irinotecan)
• Eloxatin (oxaliplatin)
• Xeloda (capecitabine)

Snippet

Sponsor: National Cancer Centre, Singapore | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: RECRUITING